While it wouldn’t be expected to reverse AD pathology, LFD interventions may present a real opportunity for improvements in cognitive functioning in obese, preclinical to early stage AD patients since some of the cognitive difficulties initially experienced by this population may actually be caused by obesity’s effects on inflammatory processes and insulin signaling, as opposed to amyloid burden. Here, INS is linked to Obesity.